Of note is the ratio of Evolus Inc's sales and general administrative expense to its total operating expenses; 98.34% of US stocks have a lower such ratio.
Revenue growth over the past 12 months for Evolus Inc comes in at 257.99%, a number that bests 97.38% of the US stocks we're tracking.
Evolus Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -84.3%, greater than the shareholder yield of just 4.59% of stocks in our set.
Stocks that are quantitatively similar to EOLS, based on their financial statements, market capitalization, and price volatility, are YAYO, MGPI, RIBT, ESNT, and NWPX.
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.
Evolus, Inc. (EOLS) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Ashwin Agarwal - Vice President, Finance, Investor Relations and Treasury David Moatazedi - President and Chief Executive Officer Mike Jafar - Chief Marketing Officer Rui Avelar - Chief Medical Officer Lauren Silvernail - Chief...